Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Analysis of efficacy and prognostic factors in transfusion-dependent thalassemia following allogeneic hematopoietic stem cell transplantation using the ‘gx-07-tm’ regimen

View Full Paper
Ask AI
Bookmark
Share

Authors

LSLingling ShiZGZhaoping GanMWMeiqing Wu

Discussion

Loading...

Member takes

Overview

Retrospective analysis showed high survival rates in transfusion-dependent thalassemia after transplantation, indicating promising outcomes with the GX-07-TM regimen.

Key Points

  • Cumulative 2-year overall survival reached 93.9%, highlighting the effectiveness of the GX-07-TM regimen.
  • A total of 1,010 patients were analyzed, revealing significant improvements in outcomes post-2020 for matched sibling donors.
  • Transplantation methods included matched sibling donors and alternative donors, with distinct outcomes reported for each.
  • Independent risk factors identified include pneumonia and age over 9 years, suggesting critical elements impacting transplant-free survival.

Cite This Study

Shi et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dfbbhttps://doi.org/10.1182/blood-2025-167
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A novel reduce toxity myeloablative conditioning regimen f-BMT improves efficacy and safety of allogeneic hematopoietic stem cell transplantation in patients with transfusion-dependent thalassemia: A multicenter clinical trial2025 · 1 citations
  2. 2Enhanced engraftment and immune recovery in thalassemia via optimized conditioning for TCRαβ⁺-depleted haploidentical transplants2025
  3. 3Fludarabine, Busulfan, Thiotepa, and Melphalan: A Novel Low‐Toxicity Myeloablative Conditioning Regimen for Haploidentical HSCT in Children and Adolescents Aged ≥7 Years With Transfusion‐Dependent β‐Thalassemia2026
  4. 4Optimizing outcomes and accessibility of matched sibling donor transplantation for severe hemoglobinopathies in low-resource settings2025
  5. 5The efficacy and safety of using low-dose cyclophosphamide, fludarabine and thymoglobulin in allogeneic hematopoietic stem cell transplantation for transfusion-dependent non-severe aplastic anemia：a retrospective study.2025